Hospital de Cabuenes

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma4 trials
• Obesity2 trials
• Ulcerative colitis2 trials
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Diffuse large B-cell lymphoma1 trial

Phase

• Phase 36 trials
• Phase 23 trials

Status

• Active, not recruiting4 trials
• Recruiting3 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• PETHEMA Foundation3 trials
• Acerta Pharma BV1 trial
• Fundacion PETHEMA1 trial
• Population Health Research Institute1 trial

Running trials

• Not yet recruiting

  Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

  NCT07901868· Phase 2· PETHEMA Foundation· Source

  Contact: Alfonso Santiago, PhD

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Pilar Varela Trastoy (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Pilar Varela Trastoy (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Pilar Varela Trastoy (principal investigator)

• Active, not recruiting

  Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

  NCT06282978· Phase 2· PETHEMA Foundation· Source

• Active, not recruiting

  Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT

  2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source

• Active, not recruiting

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

  NCT03742297· Phase 3· PETHEMA Foundation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Ulcerative colitis2 recruiting
• Crohn's disease1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source